GEHC GE HealthCare Technologies Inc.
X-Ray Apparatus & Tubes & Related Irradiation Apparatus · Nasdaq · SEC CIK 1932393 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY6.9%
TTM net income YoY-2.8%
TTM EPS YoY-2.1%
Revenue 3-yr CAGR3.9%
Net income 3-yr CAGR7.8%
Margins
Gross margin39.9%
Operating margin13.3%
Net margin10.0%
FCF margin8.7%
EBITDA margin14.8%
Returns
ROE19.9%
ROA5.8%
ROIC (approx.)13.2%
Asset turnover0.58x
Leverage & solvency
Liabilities / assets69.1%
Debt / equity0.86x
Current ratio1.30x
Interest coverage6.60x
Cash quality & payout
Operating cash flow / net income1.12x
Accruals ratio-0.7%
Payout ratio3.0%
Capex / revenue2.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $20.62B | $19.67B |
| Gross profit | $8.25B | $8.21B |
| R&D expense | $1.26B | $1.31B |
| SG&A expense | $4.22B | $4.27B |
| Operating income | $2.76B | $2.62B |
| Interest expense | $440.00M | $504.00M |
| Pretax income | $2.77B | $2.58B |
| Income tax | $614.00M | $531.00M |
| Net income | $2.08B | $1.99B |
| EBITDA | $3.05B | $2.89B |
| EPS (basic) | 4.56 | 4.37 |
| EPS (diluted) | 4.55 | 4.34 |
| Dividends declared per share | 0.14 | 0.12 |
| Weighted avg. shares (diluted) | 458.00M | 459.00M |
| Balance sheet | ||
| Cash & equivalents | $4.49B | $2.89B |
| Inventory | $2.23B | $1.94B |
| Current assets | $12.50B | $9.90B |
| Goodwill | $13.49B | $13.14B |
| Intangibles | $1.13B | $1.08B |
| Total assets | $36.91B | $33.09B |
| Current liabilities | $9.11B | $9.55B |
| Short-term debt | $502.00M | $1.50B |
| Long-term debt | $9.49B | $7.45B |
| Total debt | $10.00B | $8.95B |
| Total liabilities | $26.31B | $24.44B |
| Shareholders' equity | $10.38B | $8.45B |
| Net debt | $5.50B | $6.06B |
| Cash flow statement | ||
| Operating cash flow | $1.99B | $1.96B |
| Capital expenditure | $482.00M | $401.00M |
| Free cash flow | $1.50B | $1.55B |
| Investing cash flow | -$1.05B | -$914.00M |
| Financing cash flow | $617.00M | -$573.00M |
| Depreciation & amortization | $287.00M | $268.00M |
| Stock-based compensation | $130.00M | $125.00M |
| Dividends paid | $64.00M | $55.00M |
| Share buybacks | $200.00M | $0 |
Free plan shows the latest 2 periods; Pro shows all 5 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.